Drug-related challenges following primary total hip and knee arthroplasty
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Accepteret manuskript, 360 KB, PDF-dokument
We aimed to characterize the in-hospital analgesic use among total hip or knee arthroplasty (THA or TKA) patients, and to identify possible drug-related challenges. We identified 15 263 patients operated with a THA or TKA between 1 January 2012 and 30 April 2016. The prevalence of analgesic users and patients with potential clinically relevant drug-drug interactions (DDIs), along with the prevalence of readmission among patients with vs. without a DDI, were calculated. A DDI was defined as the combination of (A) a diuretic, an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, and an non-steroidal anti-inflammatory Drug (NSAID); (B) warfarin and an NSAID; and (C) a benzodiazepine or a benzodiazepine-related drug and an opioid. The prevalence of analgesics administered in THA and TKA patients was 99.3% and 99.1% for paracetamol and 93.8% and 98.8% for opioids, respectively. The prevalence of patients who received interaction A, B or C was 8.4%, 2.5% and 40.7%, respectively. Patients with vs. without a DDI had a higher prevalence of 30-day readmission. In conclusion, most THA and TKA patients were administered paracetamol or opioids. The prevalence of 30-day readmission was higher in patients with than in patients without a potential clinically relevant DDI.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Basic & Clinical Pharmacology & Toxicology |
Vol/bind | 129 |
Udgave nummer | 2 |
Sider (fra-til) | 139-147 |
ISSN | 1742-7835 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
Anne Mette Skov Sørensen reports grants from Tværspuljen, Helsefonden, and Aase and Ejnar Foundation during the conduct of the study; Martin Erik Nyeland reports personal fees from LEO Pharma A/S outside the submitted work; Søren Overgaard reports grants from ZimmerBiomet outside the submitted work; Astrid Blicher Schelde reports grants from Danish Regions during the conduct of the study. The other authors report no conflicts of interest.
Funding Information:
This study was supported by Danish Regions, Aase and Ejnar Danielsens Foundation, Bispebjerg and Frederiksberg Hospital, Tværspuljen, and Helsefonden.
Publisher Copyright:
© 2021 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
ID: 273652749